Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Pacira BioSciences announced the publication of positive two-year Phase 1 data for PCRX-201 in the Annals of the Rheumatic Diseases. The study of 72 patients with moderate-to-severe knee osteoarthritis demonstrated that a single intra-articular injection was well-tolerated and provided improvements in pain, stiffness, and function lasting up to 104 weeks.
Key figures
- Drug Name
- PCRX-201 (enekinragene inzadenovec)
- Phase Of Trial
- Phase 1
- Participants
- 72
- Follow up weeks
- 104
- Addressable population
- 15 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.